Using a human breast cancer cell line MDA-MB-231 cells, we examined the roles of microRNAs (miRs) in the regulation of p21, a cyclin-dependent kinase inhibitor, and the resistance to cisplatin and tubulin inhibiting anti-cancer drugs such as eribulin and paclitaxel. MDA-MB231 cells were separated into two subpopulations by the surface antigen CD44, a potential marker for cancer stem-like cells. The level of p21 protein expression was higher in CD44
+ than in CD44
-. Exposure of MDA-MB-231 cells to the above drugs led to increases in p21 protein. However, the level of p21 in CD44
+ isolated after exposure to cisplatin was significantly lower than CD44
-, suggesting that p21-dependent cell cycle suppression was blunted in CD44
+ compared with CD44
-. The oxidation rate of glutathione in CD44
+ isolated after cisplatin treatment was much lower than that in CD44
-, indicating that cisplatin induces much weaker oxidative cytotoxicity to CD44
+ than to CD44
-. Moreover, caspase-3 activity in CD44
+ isolated after exposure to cisplatin was significantly lower than that in CD44
-, indicating that CD44
+ is more resistant to cisplatin-induced apoptosis. To explore the roles of miRs in the expression of p21, MDA-MB-231 cells were treated with various miR inhibitors followed by isolation of CD44
+. Among them, inhibitors for miR-17 and miR-93 increased the expression of p21 in CD44
+, suggesting that p21 expression is suppressed by miR-17 and miR-93. Thus, the current study demonstrated that expression of CD44 is associated with drug resistance to cisplatin in MDA-MB231 cells. It was also suggested that miR-17 and miR-93 serve as inhibitors for p21, a factor involved in drug resistance.
View full abstract